首页> 外文OA文献 >Cost-effectiveness analysis of tenofovir/emtricitabine and abacavir/lamivudine in combination with efavirenz or atazanavir/ritonavir for treatment-naïve adults with HIV-1 infection in the UK, based on the AIDS Clinical Trials Group 5202 clinical trial

【2h】

Cost-effectiveness analysis of tenofovir/emtricitabine and abacavir/lamivudine in combination with efavirenz or atazanavir/ritonavir for treatment-naïve adults with HIV-1 infection in the UK, based on the AIDS Clinical Trials Group 5202 clinical trial

机译：Tenofovir / Emtricitabine和Abacavir / Lamivudine与Efaviraven或Atazanavir / Ritonavir的成本效果分析与英国HIV-1感染的治疗 - 幼稚动物治疗 - 幼稚动物，基于艾滋病临床试验组5202临床试验

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
E Wilkins; M Fisher; AJ Brogan; SE Talbird; EM La;
展开▼
作者单位

展开▼
年度 2015
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Cost-effectiveness analysis of tenofovir/emtricitabine and abacavir/lamivudine in combination with efavirenz or atazanavir/ritonavir for treatment-naive adults with HIV-1 infection in the UK, based on the AIDS Clinical Trials Group 5202 clinical trial [J] . Wilkins E., Fisher M., Brogan A. J., HIV medicine . 2016,第7期

机译：根据AIDS Clinical Trials Group 5202临床试验，将替诺福韦/恩曲他滨和阿巴卡韦/拉米夫定联合依非韦伦或阿扎那韦/利托那韦用于未接受过HIV-1感染的成人的成本效益分析
2. Cost-effectiveness analysis of tenofovir/emtricitabine and abacavir/lamivudine in combination with efavirenz or atazanavir/ritonavir for treatment-naive adults with HIV-1 infection in the UK, based on the AIDS Clinical Trials Group 5202 clinical trial [J] . Wilkins E., Fisher M., Brogan A. J., HIV medicine . 2016,第7期

机译：基于艾滋病临床试验组5202临床试验，崇高韦洛茨或阿巴伐/拉米凡押，与艾草韦或阿巴帕维尔/拉米夫尔/拉米夫鲁德的成本效应分析与英国有艾滋病毒1感染的治疗 - 天真的成人
3. Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG A5202. [J] . McComsey GA, Kitch D, Daar ES, The Journal of Infectious Diseases . 2011,第12期

机译：初次接受抗逆转录病毒治疗的人的骨矿物质密度和骨折随机接受阿巴卡韦-拉米夫定或替诺福韦二吡呋酯富马酸-恩曲他滨联合依非韦伦或阿扎那韦-利托那韦：艾滋病临床试验组A5224s，是ACTG A5202的一项子研究。
4. Older Adults' Perceptions of Video Game Training in the Intervention Comparative Effectiveness for Adult Cognitive Training (ICE-ACT) Clinical Trial: An Exploratory Analysis [C] . Ronald Andringa, Erin R. Harell, Michael Dieciuc, International Conference on Human Aspects of IT for the Aged Population;International Conference on Human-Computer Interaction . 2019

机译：老年人对视频游戏培训的干预感知对成人认知培训（ICE-ACT）临床试验的比较有效性：探索性分析
5. Cost effectiveness analysis of abacavir/lamivudine versus tenofovir/emtricitabine combination therapy as part of highly active antiretroviral therapy in treatment naive HIV-infected patients. [D] . Giguere, Pierre. 2010

机译：阿巴卡韦/拉米夫定与替诺福韦/恩曲他滨联合疗法作为高活性抗逆转录病毒疗法治疗未受HIV感染的患者的成本效益分析。
6. Editors Choice: Bone Mineral Density and Fractures in Antiretroviral-Naive Persons Randomized to Receive Abacavir-Lamivudine or Tenofovir Disoproxil Fumarate-Emtricitabine Along With Efavirenz or Atazanavir-Ritonavir: AIDS Clinical Trials Group A5224s a Substudy of ACTG A5202 [O] . Grace A. McComsey, Douglas Kitch, Eric S. Daar, -1

机译：编辑选择：抗逆转录病毒纯种患者的骨矿物质密度和骨折随机接受阿巴卡韦-拉米夫定或替诺福韦替诺福韦酯富马酸酯-依米他滨治疗依法韦仑或阿扎那韦-利托那韦：AIDS临床试验A5224sACTG A520的子研究
7. Bone Mineral Density and Fractures in Antiretroviral-Naive Persons Randomized to Receive Abacavir-Lamivudine or Tenofovir Disoproxil Fumarate-Emtricitabine Along With Efavirenz or Atazanavir-Ritonavir: AIDS Clinical Trials Group A5224s, a Substudy of ACTG A5202 [O] . McComsey, Grace A., Kitch, Douglas, Daar, Eric S., 2011

机译：抗逆转录病毒天真患者的骨矿物质密度和骨折，随机接受阿巴卡韦-拉米夫定或替诺福韦地替莫韦酯富马酸酯-依米他滨与依非韦伦或阿扎那韦-利托那韦的联合治疗：AIDS临床试验组A5224s，是ACTG A5202的一项子研究

Cost-effectiveness analysis of tenofovir/emtricitabine and abacavir/lamivudine in combination with efavirenz or atazanavir/ritonavir for treatment-naïve adults with HIV-1 infection in the UK, based on the AIDS Clinical Trials Group 5202 clinical trial

著录项

引文网络

相似文献

相关主题

期刊订阅